| 引用本文: | 高孟,高丽美,吴洁,陈刚,李剑波,周冬,罗永能,庄昉成.治疗性人乳头瘤病毒16型疫苗的人参皂苷单体佐剂筛选研究[J].中国现代应用药学,2019,36(4):406-410. |
| GAO Meng,GAO Limei,WU Jie,CHEN Gang,LI Jianbo,ZHOU Dong,LUO Yongneng,ZHUANG Fangcheng.Screening of Ginsenoside Adjuvant with Therapeutic Human Papillomavirus-16 Recombinant Vaccine[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(4):406-410. |
|
| 摘要: |
| 目的 研究不同人参皂苷单体佐剂对治疗性人乳头瘤病毒16型（human papillomavirus type 16，HPV16）重组疫苗免疫效果的影响，筛选合适的人参皂苷单体作为候选佐剂。方法 选择5种人参皂苷单体Rb1、Rh1-1、Rh1-2、Rg1、Rg3，分别与治疗性HPV16重组疫苗联合免疫C57BL/6小鼠，用酶联免疫斑点试验比较各组小鼠的特异性细胞免疫应答水平，同时比较这5种人参皂苷单体对治疗性HPV16重组疫苗抑制小鼠肿瘤生长的影响。结果 人参皂苷单体Rg1、Rb1可以显著提高治疗性HPV16重组疫苗特异性细胞免疫应答（HPV+Rg1组vs HPV组：t=3.729，P=0.006；HPV+Rb1组vs HPV组：t=3.204，P=0.013），同时可以在小鼠特异性肿瘤模型建立4周时，有效抑制肿瘤的生长水平（HPV+Rg1组vs HPV组：t=2.318，P=0.032；HPV+Rb1组vs HPV组：t=2.258，P=0.037）。结论 人参皂苷单体Rg1、Rb1能在C57BL/6小鼠中提高治疗性HPV16重组疫苗的特异性免疫效果，有望成为候选佐剂。 |
| 关键词: 人参皂苷 T细胞免疫 人乳头瘤病毒16 治疗性疫苗 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.04.005 |
| 分类号:R285.5 |
| 基金项目:浙江省医药卫生科技计划项目（2015KYB095）；浙江省中医药科技计划项目（2016ZA043）；浙江省医学生物工程疫苗研发重点实验室（2008F3022）；浙江省科技厅2018年院士基金（CB1835D） |
|
| Screening of Ginsenoside Adjuvant with Therapeutic Human Papillomavirus-16 Recombinant Vaccine |
|
GAO Meng, GAO Limei, WU Jie, CHEN Gang, LI Jianbo, ZHOU Dong, LUO Yongneng, ZHUANG Fangcheng
|
|
Institute of Viral Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
|
| Abstract: |
| OBJECTIVE To screen different ginsenosides as candidate adjuvant on therapeutic human papillomavirus-16 (HPV16) recombinant vaccine by comparing their effect on immune response. METHODS Five ginsenosides(Rb1, Rh1-1, Rh1-2, Rg1, Rg3) were selected and immunized with HPV16 recombinant vaccine on C57BL/6 mice. The level of cellular immune responses was detected by ELISPOT in mice, and the effect of ginsenosides on tumor growth inhibition of HPV16 recombinant vaccine was observed. RESULTS Ginsenosides Rg1 and Rb1 could significantly increase the specific cellular immune response of therapeutic HPV16 recombinant vaccine (HPV+Rg1 group vs HPV group:t=3.729, P=0.006; HPV+Rb1 group vs HPV group:t=3.204, P=0.013) and higher tumor growth inhibition in week four (HPV+Rg1 group vs HPV group:t=2.318, P=0.032; HPV+Rb1 group vs HPV group:t=2.258, P=0.037). CONCLUSION The ginsenosides Rg1 and Rb1 can improve the specificity immune effect of HPV16 recombinant vaccine in C57BL/6 mice, and maybe can become candidate adjuvants. |
| Key words: ginsenosides T cell immunity human papillomavirus 16 therapeutic vaccine |
